MX2019002894A - Combinaciones con un peptido ciclado con la estructura de la base. - Google Patents

Combinaciones con un peptido ciclado con la estructura de la base.

Info

Publication number
MX2019002894A
MX2019002894A MX2019002894A MX2019002894A MX2019002894A MX 2019002894 A MX2019002894 A MX 2019002894A MX 2019002894 A MX2019002894 A MX 2019002894A MX 2019002894 A MX2019002894 A MX 2019002894A MX 2019002894 A MX2019002894 A MX 2019002894A
Authority
MX
Mexico
Prior art keywords
dab
diseases
infections
trp
backbone
Prior art date
Application number
MX2019002894A
Other languages
English (en)
Inventor
E Dale Glenn
Obrecht Daniel
Bernardini Francesca
Original Assignee
Polyphor Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polyphor Ag filed Critical Polyphor Ag
Publication of MX2019002894A publication Critical patent/MX2019002894A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin

Abstract

Una combinación novedosa que comprende un péptidomimético de ß-horquilla de la fórmula (Thr-Trp-Ile-Dab-Orn-DDAB-Dab-Trp-Dab-Da b-Ala-Ser-DPro-Pro) (I), y otro compuesto con actividad antibiótica, que permiten el control terapéutico de infecciones bacterianas específicas en humanos o animales a dosis de los compuestos individuales más bajos que cualquiera de los compuestos administrados solos. La combinación se puede utilizar como un medicamento para tratar por ejemplo, infecciones de la piel o tejidos blandos; infecciones de ojos, oídos, torrente sanguíneo, o intra-abdominales; infecciones relacionadas con enfermedades respiratorias, enfermedades óseas, enfermedades cardiovasculares, enfermedades genitourinales, o enfermedades gastrointestinales.
MX2019002894A 2012-08-08 2015-02-06 Combinaciones con un peptido ciclado con la estructura de la base. MX2019002894A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12005743 2012-08-08

Publications (1)

Publication Number Publication Date
MX2019002894A true MX2019002894A (es) 2019-07-04

Family

ID=46796225

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015001684A MX366993B (es) 2012-08-08 2013-08-07 Combinaciones con un peptido ciclado con la estructura de la base.
MX2019002894A MX2019002894A (es) 2012-08-08 2015-02-06 Combinaciones con un peptido ciclado con la estructura de la base.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015001684A MX366993B (es) 2012-08-08 2013-08-07 Combinaciones con un peptido ciclado con la estructura de la base.

Country Status (26)

Country Link
US (1) US9814754B2 (es)
EP (1) EP2882771B1 (es)
JP (2) JP6486271B2 (es)
KR (1) KR102142870B1 (es)
CN (1) CN104684924B (es)
AU (1) AU2013301576B2 (es)
BR (1) BR112015002726B1 (es)
CA (1) CA2887388C (es)
CY (1) CY1120727T1 (es)
DK (1) DK2882771T3 (es)
EA (1) EA030524B1 (es)
ES (1) ES2640289T3 (es)
HK (1) HK1207868A1 (es)
HR (1) HRP20171385T1 (es)
HU (1) HUE036289T2 (es)
IL (1) IL236696B (es)
LT (1) LT2882771T (es)
MX (2) MX366993B (es)
NZ (1) NZ703723A (es)
PL (1) PL2882771T3 (es)
PT (1) PT2882771T (es)
RS (1) RS56350B1 (es)
SG (1) SG11201500130WA (es)
SI (1) SI2882771T1 (es)
WO (1) WO2014023766A1 (es)
ZA (1) ZA201500277B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101479148B1 (ko) 2007-02-28 2015-01-05 폴리포 리미티드 주형 고정된 펩타이드 모방체
KR101692992B1 (ko) 2015-05-20 2017-01-17 연세대학교 산학협력단 고리형 펩타이드의 사전 활성화 합성방법 및 이에 따라 합성된 고리형 펩타이드
MX2023005982A (es) * 2020-11-23 2023-08-15 Spexis Ag Composiciones de un peptidomimetico de horquilla beta y formas de dosificacion en aerosol del mismo.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003232253A1 (en) * 2003-05-02 2004-11-23 Polyphor Ag Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity
WO2007079597A1 (en) * 2006-01-16 2007-07-19 Polyphor Ltd. Template - fixed peptidomimetics with antimicrobial activity
WO2010017273A2 (en) 2008-08-06 2010-02-11 Wyeth Tigecycline formulations

Also Published As

Publication number Publication date
AU2013301576A1 (en) 2015-02-05
JP2015524461A (ja) 2015-08-24
HUE036289T2 (hu) 2018-06-28
WO2014023766A1 (en) 2014-02-13
CN104684924B (zh) 2018-04-17
EA030524B1 (ru) 2018-08-31
IL236696A0 (en) 2015-02-26
MX366993B (es) 2019-08-02
US9814754B2 (en) 2017-11-14
CN104684924A (zh) 2015-06-03
LT2882771T (lt) 2017-09-25
NZ703723A (en) 2018-03-23
KR20150038611A (ko) 2015-04-08
BR112015002726B1 (pt) 2022-10-04
BR112015002726A2 (pt) 2017-07-04
ZA201500277B (en) 2015-12-23
HRP20171385T1 (hr) 2017-11-03
BR112015002726A8 (pt) 2018-01-16
DK2882771T3 (en) 2017-09-25
CA2887388A1 (en) 2014-02-13
SI2882771T1 (sl) 2017-11-30
ES2640289T3 (es) 2017-11-02
MX2015001684A (es) 2015-04-10
US20150224168A1 (en) 2015-08-13
CA2887388C (en) 2021-02-16
JP6486271B2 (ja) 2019-03-20
KR102142870B1 (ko) 2020-08-11
EP2882771A1 (en) 2015-06-17
EP2882771B1 (en) 2017-06-14
IL236696B (en) 2019-06-30
AU2013301576B2 (en) 2017-10-19
HK1207868A1 (en) 2016-02-12
PL2882771T3 (pl) 2018-01-31
PT2882771T (pt) 2017-09-22
SG11201500130WA (en) 2015-03-30
CY1120727T1 (el) 2019-12-11
RS56350B1 (sr) 2017-12-29
EA201590350A1 (ru) 2015-07-30
JP2018109008A (ja) 2018-07-12

Similar Documents

Publication Publication Date Title
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
UA104320C2 (ru) Фармацевтическая композиция на основе митохондриально-адресованного антиоксиданта для применения в медицинской и ветеринарной офтальмологии
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
MX337830B (es) Peptidos utiles en el tratamiento y/o cuidado de la piel y/o cabello y su uso en composiciones cosmeticas o farmaceuticas.
WO2009043458A3 (en) Use of oxytocin to treat many diseases
NZ707377A (en) Combination therapy methods for treating proliferative diseases
ES2397889A1 (es) PÉPTIDOS MODULADORES DE PGC-1Alfa.
NZ701607A (en) Therapeutic use of chardonnay seed products
BR112014015482A2 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
ATE553772T1 (de) Verwendung von lvv-hämorphin-6 und optional af12198 als therapeutische(s) mittel
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
NZ605841A (en) Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
NZ604662A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
MX2014001393A (es) 3-(bifenil-3-il)-4-hidroxi-8-metoxi-1-azaespiro[4.5]dec-3-en-2-on as sustituidas.
WO2009046864A3 (en) Use of the human pancreatic polypeptide as a therapeutic agent
MX2019002894A (es) Combinaciones con un peptido ciclado con la estructura de la base.
WO2009046860A3 (en) Use of dago as a therapeutic agent
MX2019002657A (es) Combinaciones con un peptido con esqueleto ciclado.
WO2011056871A3 (en) Rhamnolipid mechanism
EP3590338A3 (en) Medical treatments based on anamorelin
IN2014CN03333A (es)
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
EA201791895A1 (ru) Дозы и способы введения телаванцина